Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series

Breast

Volumn 16, Issue 4, 2007, Pages 367-374

  Hagen, Anne I ^a   Kvistad, Kjell Arne ^b   Maehle, Lovise ^c   Holmen, Marit Muri ^c   Aase, Hildegunn ^d   Styr, Bodil ^e   Vabø, Anita ^c   Apold, Jaran ^d   Skaane, Per ^f   Møller, Pål ^c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

BRCA1 2 mutation carriers; Breast MRI; DCIS; XRM

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GADODIAMIDE; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SCREENING; CANCER STAGING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EARLY DIAGNOSIS; ECHOGRAPHY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 34547421929     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.01.006     Document Type: Article

References (37)

1. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
2. Wooster R., Neuhausen S.L., Mangion J., et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 (1994) 2088-2090
3. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62 (1998) 676-689
4. Heimdal K., Maehle L., Apold J., Pedersen J.C., and Moller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 39 (2003) 2205-2213
5. King M.-C., Marks J.H., Mandell J.B., and The New York breast Cancer Study Group. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. Science 302 (2003) 643-643
6. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349 (1997) 1505-1510
7. Lynch B.J., Holden J.A., Buys S.S., Neuhausen S.L., and Gaffney D.K. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 29 (1998) 1140-1144
8. Johannsson O.T., Idvall I., Anderson C., et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33 (1997) 362-371
9. Foulkes W.D., Wong N., Brunet J.-S., et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Canc Res 3 (1997) 2465-2469
10. Ansquer Y., Gautier C., Fourquet A., Asselain B., Stoppa-Lyonnet D., and Institut Curie Breast Cancer Group. Survival in early-onset BRCA1 breast-cancer patients. Lancet 352 (1998) 541
11. Stoppa-Lyonnet D., Ansquer Y., Dreyfus H., et al. Familal invasive breast cancers. Worse outcome related to BRCA1 mutations. J Clin Oncol 18 (2000) 4053-4059
12. Foulkes W.D., Chappuis P.O., Wong N., et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 11 (2000) 307-313
13. Møller P., Borg A., Evans D.G., et al. Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101 (2002) 555-559
14. Robson M.E., Chappuis P.O., Satagopan J., et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6 (2004) R8-R17
15. Moller P., Evans G., Haites N., et al. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Dis Markers 15 (1999) 207-211
16. Tilanus-Linthorst M.M., Bartels C.C., Obdeijn A.I., and Oudkerk M. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 36 (2000) 514-519
17. Stoutjesdijk M.J., Boetes C., Jager G.J., et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 93 (2001) 1095-1102
18. Warner E., Plewes D.B., Shumak R.S., et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19 (2001) 3524-3531
19. Podo F., Sardanelli F., Canese R., et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 21 (2002) 115-124
20. Warner E., Plewes D.B., Hill K.A., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292 (2004) 1317-1325
21. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 (2004) 427-437
22. Leach M.O., Boggis C.R., Dixon A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365 (2005) 1769-1778
23. Kuhl C.K., Schrading S., Leutner C.C., et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23 (2005) 8469-8476
24. The Norwegian Mammography Screening programme Guidelines for mammography. Quality Assurance Manual 1996; 53.
25. Harms S.E. Technical report of the international working group on breast MRI. J Magn Reson Imag 10 (1999) 979
26. Lehman C.D., Blume J.D., Weatherall P., et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103 (2005) 1898-1905
27. Kuhl C.K., Schmutzler R.K., Leutner C.C., et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215 (2000) 267-279
28. Hofvind S., Wang H., and Thoresen S. Do the results of the process indicators in the Norwegian Breast Cancer Screening Program predict future mortality reduction from breast cancer?. Acta Oncol 43 (2004) 467-473
29. Rebbeck T.R., Levin A.R., Eisen A., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 (1999) 1475-1479
30. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (2002) 1616-1622
31. Sun C.C., Lenoir G., Lynch H., and Narod S.A. In-situ breast cancer and BRCA1. Lancet 348 (1996) 408
32. Kauff N.D., Brogi E., Scheuer L., et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97 (2003) 1601-1608
33. Claus E.B., Petruzella S., Matloff E., and Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293 (2005) 964-969
34. Peto J., Collins N., Barfoot R., et al. Prevalence of BRCA 1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91 (1999) 943-949
35. Syrjäkoski K., Vahteristo P., Eerola H., et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92 (2000) 1529-1531
36. Komenaka I.K., Ditkoff B.A., Joseph K.A., et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 100 (2004) 2079-2083
37. Morris E.A., Liberman L., Ballon D.J., et al. MRI of occult breast carcinoma in a high-risk population. Am J Radiol 181 (2003) 619-626